Novo Nordisk's Strategic Shift Amidst U.S. Pricing Pressure

Novo Nordisk's Strategic Shift Amidst U.S. Pricing Pressure

Novo Nordisk's Strategic Shift Amidst U.S. Pricing Pressure Novo Nordisk has announced the appointment of Greg Miley, a seasoned U.S. pharmaceutical executive, as its new global head of corporate affairs.This strategic hiring decision comes as the company navigates growing pressure from U.S. President Donald Trump, particularly concerning drug pricing strategies.Miley, who recently held a senior vice presidency in government affairs at AbbVie, c…

Trump's prank on Eli Lilly and Novo Nordisk

Trump has the power to call the shots. And this time, things went badly for Novo Nordisk and Eli Lilly. Indeed, after promising Ozempic and similar drugs at $150 a month (from the current $1,000-$1,300), the pharmaceutical companies' stocks plummeted. Facts, numbers, and comments Even the best can fall. US President Donald Trump's comments about reducing the price of GLP-1 weight-loss drugs, particularly Novo Nordisk's Ozempic, triggered an imme…